News Hub | News Direct

Lifestyle

Beverage: Coffee/Tea/Non-Alcoholic Beverage: Spirits/Beer/Wine Casino/Gaming Fashion Food/Cooking/Baking Health & Fitness Home Goods Hospitality Leisure Activities & Hobbies Parenting Pets Photography Seniors Travel & Tourism
Article thumbnail News Release

Austin-based chief medical officer commits to health equity in Central Texas by joining local American Heart Association Board of Directors

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a leader in brain injury rehabilitation services, and The American Heart Association (AHA), the world’s leading nonprofit organization focused on heart and brain health for all, today announced Dr. Matthew Ashley as a new member of the AHA’s Board of Directors in Central Texas. Dr. Ashley is the chief medical officer for CNS. “I am honored to join the Central Texas American Heart Association board and serve our community by improving heart health and stroke awareness with the AHA,” said Dr. Ashley. “For nearly 100 years, the American Heart Association has been ensuring longer, healthier lives through innovative educational efforts including stroke prevention and treatment. I look forward to our partnership for large-scale community efforts focused on public education and awareness regarding brain injuries.” Earlier this year, the AHA and CNS announced that they are working together to deepen connections with healthcare providers, patients and caregivers while raising awareness of post-stroke care throughout Texas and California. “The Central Texas Board of Directors continues to guide the American Heart Association as we address health disparities throughout our area,” said Sara Harwood, Region Senior Vice President of the American Heart Association. “The addition of Centre for Neuro Skills and Matt Ashley to our Board brings more insight and ideas as we deepen our understanding and ready for action on all aspects of health and well-being.” During Dr. Ashley’s nine-year tenure at CNS, he has served as a consulting neurologist, treating a diverse spectrum of patients recovering from traumatic and acquired brain injury. Dr. Ashley is a noted speaker, who lectures at universities and seminars focusing on stroke, epilepsy, dementia, neuroradiology and brain injury rehabilitation. Dr. Ashley received both his medical and juris doctor degrees from Southern Illinois University. He completed a neurology residency at UCLA, as well as a neurological rehabilitation fellowship at the university’s renowned Neurological Rehabilitation and Research Unit. CNS opened its newest clinic in Austin in June, 2021. The 17,000 square ft. facility can serve 60 patients and is located at 14425 Falconhead Blvd. ### About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information, visit neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. For a video overview of CNS, visit our YouTube channel. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Visit heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1. Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com American Heart Association Megan Jameson +1 512-338-2639 megan.jameson@heart.org Company Website https://www.neuroskills.com/

May 03, 2023 08:32 AM Pacific Daylight Time

Image
Article thumbnail News Release

Emergent Health Announces Its Return to the “Pink Current Information” Tier on OTC Markets

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space, is pleased to announce that it has regained its “Pink Current Information” status with the OTC Markets, a major milestone in the company's continued growth and development and is now current with all required mandatory disclosure filings again. Jim Morrison, former L'Oréal President and Emergent’s full-time CEO stated “We’ve been working diligently with OTC Markets since being classified as “Pink Sheet Limited Information” several weeks ago and took all the necessary steps to regain “Pink Current Information” status. Achieving this status is a testament to Emergent’s commitment to excellence and full transparency with the intent to create long-term trust and value for our shareholders. Moving forward, we have taken steps to ensure this never occurs again with regard to OTC Market mandatory disclosure requirements. This achievement would not have been possible without the hard work and dedication of our entire team, and we are grateful for their efforts”. Yesterday on May 2, 2023, Emergent announced revenues of $373,406 for the quarter ended December 31, 2022 as compared to $185,471 for the quarter ended September 30, 2022, an increase of over 100% and revenues of $574,613 for the Year Ended December 31, 2022 as compared to $119,567 for the year ended December 31, 2021, an increase of over 380%. The financial statement can be viewed in its entirety at OTC Markets. The global b iologics market size was valued at US $366.43 billion in 2021 and it is expected to hit over US$ 719.84 billion by 2030 with a noteworthy CAGR of 7.8% from 2022 to 2030. A biologic medication is a product that is made from live organisms and contains living organism components. Examples of biologics are Recombinant protein, tissues, allergens, genes, cells, blood components, blood, and vaccinations are all examples of biologics. Examples of what can be treated are Anemia, hemophilia, chronic migraine, hepatitis B, rheumatoid arthritis, inflammatory bowel disease, and other disorders and infections are treated with biologics. Our focus is on aesthetics cosmetics and men’s and women’s health, but also wound care and tissue regeneration. Various government efforts, higher share of biologics in the market, and rising use of biopharmaceuticals over chemically produced molecules, and many other factors are driving the biologics market expansion in the forecast period. ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website i nfo@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 03, 2023 10:53 AM Eastern Daylight Time

Article thumbnail News Release

AI Tool Predicts Colon Cancer Survivorship and Response to Treatment

MarketJar

Harvard Medical School and National Cheng Kung University in Taiwan have designed an artificial intelligence (AI) algorithm to improve colorectal cancer prognosis and treatment options. The new technique uses microscopic images of tumor samples to reliably predict colorectal tumor aggressiveness. It predicts survival with and without disease recurrence and the optimum treatment. The new approach may help clinicians recommend more intense follow-ups, aggressive treatments, or clinical trials of newer drugs for individuals with poor prognosis. In areas with limited access to advanced pathology and tumor genetic sequencing, the strategy may be useful. This new AI tool goes beyond mimicking or optimizing human expertise and can see visual patterns on microscope images that the naked eye cannot. The algorithm was trained with patients' ages, sexes, cancer stages, and results using records from almost 2,000 colorectal cancer patients. The tumor's genomic, epigenetic, protein, and metabolic profiles were inputted. The model pathologist was then presented tumor samples and instructed to look for visual markers of tumor types, genetic mutations, epigenetic alterations, disease progression, and patient survival. The researchers showed the model novel pictures of tumor samples from multiple patients to test its "real-world" performance. To evaluate its efficacy, they matched its results to real patients and other clinical data. After diagnosis, survival time and cancer-free years were accurately predicted. The technology also projected how a patient's tumor would respond to certain medications based on genetic variations that made the cancer more or less likely to form or spread. The technique outperformed pathologists and cutting-edge AI algorithms. The researchers believe this approach could assist guide treatment decisions in cases when resources are short or genetic sequencing of tumor tissue is not possible. It could help clinicians and patients navigate colorectal cancer, which kills 1 million people globally each year. When it comes to combating colon cancer, early detection is key. It’s also important that cancer detection is simple, accessible, and affordable. Up until recently, a colonoscopy was the most accurate way to detect colon cancer. However, over one-third of eligible individuals refuse to undergo a colonoscopy, which is why non-invasive alternatives are needed. Mainz Biomed ( NASDAQ:MYNZ ) is the company behind ColoAlert, a highly accurate and easy-to-use at-home screening test for colorectal cancer (CRC). This product is the first DNA-based screening test for colorectal cancer and is already approved in the European Union. Revolutionary At-Home Cancer Screening Test Moves Toward FDA Approval Mainz Biomed 's flagship product ColoAlert, which is based on PCR technology, detects more cases of colorectal cancer than other stool tests and enables for early diagnosis. The product is already commercially available in some EU nations through a network of top independent laboratories, corporate health programs, and direct sales and the company is working towards US approval. The company has already successfully completed its pre-submission process, and IRB approval for its pivotal FDA study, ReconAAsense. That means that FDA approval could potentially be in the future and if that happens, it could send this company into a new dimension. ColoAlert will be tested in a pivotal FDA-registration trial 'ReconAAsense' to acquire commercial approval in the United States. Once licensed in the US, Mainz Biomed ’s goal is to build scalable distribution across the country through a collaborative partner program with regional and national laboratory service providers. Mainz Biomed has joined Eurofins GeLaMed to its network of lab partners delivering PCR test kit processing of ColoAlert. Eurofins GeLaMed is part of Eurofins Scientific, a multinational laboratory business with over 61,000 people in 61 countries and 450 million tests per year. It has four facilities in Germany. Eurofins GeLaMed offers advanced diagnostics in human genetics, medical microbiology, laboratory medicine, and molecular diagnostics in eleven medical departments. GeLaMed's over 500 staff process more than 15,000 orders each day and offer more than 2,000 analytical methods from their laboratory medicine and microbiological portfolios under medical professionals. Eurofins Business Line Director Clinical Diagnostics DACH Marcus Cholewa said he was excited about Mainz Biomed and Eurofins GeLaMed's collaboration because Eurofins always provides excellent customer service, quality, advanced analytical solutions, and the most comprehensive testing methods. He also said that Eurofins has a history of providing innovative and high-value diagnostic testing solutions, and that by working, they might help identify colorectal cancer (CRC) and give patients individualized information to manage their health. Under the agreement, Eurofins GeLaMed will offer ColoAlert at its testing sites and Mainz Biomed will help with physician and patient education programs for March Colorectal Cancer Awareness Month, emphasizing the importance of early screening for CRC detection and prevention. Please visit this link for additional information on Mainz Biomed ( NASDAQ:MYNZ ) and its projects. Disclaimer 1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector. 2) The Article was issued on behalf of and sponsored by, Mainz Biomed NV. Market Jar Media Inc. has or expects to receive from Mainz Biomed NV’s Digital Marketing Agency of Record (Native Ads Inc.) seventy three thousand three hundred forty USD for 17 days (13 business days). 3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. Market Jar has not independently verified or otherwise investigated all such information. None of Market Jar or any of their respective affiliates, guarantee the accuracy or completeness of any such information. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy. 4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com. 5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article. 6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect management's expectations regarding Mainz Biomed NV’s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Mainz Biomed NV’s industry; (b) market opportunity; (c) Mainz Biomed NV’s business plans and strategies; (d) services that Mainz Biomed NV intends to offer; (e) Mainz Biomed NV’s milestone projections and targets; (f) Mainz Biomed NV’s expectations regarding receipt of approval for regulatory applications; (g) Mainz Biomed NV’s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Mainz Biomed NV’s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Mainz Biomed NV’s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Mainz Biomed NV’s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Mainz Biomed NV’s ability to enter into contractual arrangements with additional Pharmacies; (e) the accuracy of budgeted costs and expenditures; (f) Mainz Biomed NV’s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Mainz Biomed NV to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Mainz Biomed NV’s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact Mainz Biomed NV’s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Mainz Biomed NV’s business operations (e) Mainz Biomed NV may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, Mainz Biomed NV undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does Mainz Biomed NV nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither Mainz Biomed NV nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document. 7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Mainz Biomed NV or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Mainz Biomed NV or such entities and are not necessarily indicative of future performance of Mainz Biomed NV or such entities. Contact Details James Young +1 800-340-9767 campaigns@pressreach.com Company Website https://pressreach.com

May 03, 2023 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

High School Football National Showcase Returns to Broward County in August 2023

Campus Multimedia

Broward Education Foundation (BEF), a 501(c)3 that supports educational enhancements for the 6 th largest school district in the country, today announced the return of the second annual High School Football National Showcase to Broward County, FL, from Aug. 24-26, 2023. The national showcase will feature 7 of the top 10 ranked High School football teams in the country and will include numerous 4- and 5-star college prospects. ESPN will be broadcasting two of the matchups featuring St. John Bosco (CA) vs St. Thomas Aquinas (NJ) and St. Frances Academy (MD) vs Chaminade-Madonna (FL) which will played at the Brian Piccolo Memorial Stadium on the campus of St. Thomas Aquinas. For a full schedule and game matchups, go to browardedfoundation.org. “Broward County is one of the most talent-rich high school football areas in the country and we look forward to welcoming other elite teams to south Florida,” said James A. Knapp, Director of Advancement, Broward Education Foundation. “The National High School Football Showcase in Broward County is a premier event that celebrates amazing teams, players, and coaches. The return of the Broward County Football Showcase will host a hotbed of future star talent over a weekend that will capture that nation’s attention as top-ranked high school athletes face off in person and streamed across ESPN and FloSports. Campus Multimedia will act as the exclusive strategic sponsorship partner for the High School National Football Showcase and will be responsible for commercial partnerships. Campus Multimedia has a passion to support the nation’s 77,000+ schools by bringing brand generosity to students, schools, and school districts. This mission aligns with Broward County’s values and hopes to see its community prosper. About Broward County Education Foundation Broward Education Foundation is the only 501(c)3 charitable organization solely dedicated to supporting Broward County Public Schools and serves as a catalyst for educational excellence by providing teacher grants to fund development of innovative curriculum that advances Pre K-12 achievement; vitally needed school supplies for Title I school students, and scholarships for qualified high school seniors. Established in 1983, the non-profit Broward Education Foundation contributes more than $3 million to Broward County Public Schools annually. About Campus Multimedia Campus Multimedia (CM) is on a mission to improve school life for students, teachers, and school districts through brand partnership programs that meet school needs. Its extensive network of 77,000+ school relationships creates an unparalleled impact for brands to step inside schools at scale with mutually beneficial goals. As the leader in school marketing execution, CM creates platforms for brands to achieve their goals and schools to receive resources. Learn more at campusmultimedia.com ### Contact Details Eric Nemeth nemeth@ericpr.com Company Website https://www.campusmultimedia.com/

May 03, 2023 08:57 AM Eastern Daylight Time

Article thumbnail News Release

NAVEX Opens Nominations for 2023 Customer Excellence Awards

NAVEX Global

NAVEX, the leader in integrated risk and compliance management software, today announced nominations are now open for the third annual NAVEX Customer Excellence Awards. This prestigious award acknowledges and celebrates the exceptional performance of NAVEX customers’ ethics, compliance and integrated risk management programs. The nomination window will be open until July 12, 2023. Previous Customer Excellence Award winners include Dell Technologies, Castolin Eutectic Holding GmbH, Jacksonville Transportation Authority and Genpact. Interested NAVEX customers can submit their entry today via the NAVEX Customer Excellence Award website. “A robust risk and compliance program is fundamental to creating and maintaining a highly motivated workplace culture,” said Steve Chapman, Chief Customer Officer at NAVEX. “Our annual excellence awards recognize especially strong programs that demonstrate measurable impact on business success. We look forward to seeing all of this year’s nominations.” The Customer Excellence Awards recognize exceptional program performances from NAVEX's 13,000+ customers worldwide, covering 70 million employees, categorized by company size and across three categories. Ethics & Compliance – Recognizes the exceptional ability to identify and mitigate risks, provide meaningful insights into corporate culture and drive risk aware decision-making through E&C programs. Integrated Risk Management – Recognizes the exceptional ability to adapt to specific risk landscapes, bring visibility to risk across the organization and use informed data to influence decisions that ultimately make for a more resilient and successful business. GRC Program of the Year – Recognizes the exceptional ability to break down silos across the business to align ethics and compliance, and/or integrated risk management, resulting in a comprehensive risk and compliance management program that provides efficiency and actionable insights. As in years past, an expert panel of judges will determine the winners, consisting of some of the most respected names in the industry, including Vera Cherepanova, Studio Etica; Matt Kelly, Radical Compliance; Michael Volkov, The Volkov Law Group; Kyle Welch, George Washington School of Business; Carol Williams, Strategic Decision Solutions; along with NAVEX executives Florian Haarhaus, International General Manager; Steve Chapman, Chief Customer Officer; and Carrie Penman, Chief Risk & Compliance Officer. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Scott Levesque +1 617-388-5773 scott.levesque@navex.com Company Website https://www.navex.com

May 03, 2023 08:30 AM Eastern Daylight Time

Article thumbnail News Release

WagerWire Welcomes BetMGM, Caesars, SuperBook Sports, and Others Into Media Affiliate Network

WagerWire

WagerWire, a first-of-its-kind platform that empowers bettors to buy and sell active sports bets announced today affiliate deals with nine operators including BetMGM, Caesars, SuperBook Sports, Unibet, Tipico, RSI’s BetRivers & SugarHouse, and 888’s SISportsbook, with more to be announced soon. WagerWire onboards bettors to these partner sportsbooks through its original in-house content produced by its recently launched media network and soon to be launched mobile app. The company shares content on its social media channels and hosts it on the Community Page of its website, which is home to unique insights, viewpoints and written commentaries created by members of its rapidly growing community. The site also features proprietary tools like its “Bet Value Calculator,” which instantly calculates the fair market value of any bet. “WagerWire scratches an itch that has existed in the industry for a long time. There’s a lot to love about this app.” said Liam Roth of Caesars. “Between connecting to your favorite sportsbook, tracking your bet’s real time value, and being part of a community, WagerWire shows there’s never been a better time to be a sports bettor. At Caesars we’re really excited to partner with WagerWire in hopes we can both bring in and continue to re-engage customers in this exciting new way.” In adherence to its strict commitment to regulatory compliance, WagerWire applied and was approved for vendor affiliate licenses in a number of gaming states prior to beginning services. WagerWire is now authorized to operate in 16 states, D.C., Ontario and Puerto Rico. In recognition of its rapid accomplishments in the industry, WagerWire was shortlisted among industry giants for SBC North America’s Sports Affiliate of the Year Award 2023. A hand-picked judging panel from the top of the industry will determine this year’s winners on May 11 at the New York Hilton Midtown. “This is an exciting milestone and represents the achievement of the next step in the roadmap of our media network” said Zach Doctor, co-founder and CEO of WagerWire. “We’ve built WagerWire through a ‘community first’ approach focused on education, responsibility and fun. The addition of these iconic brands to our partnership group sets a strong foundation for the next phase of our growth and the rollout of our betting marketplace.” WagerWire first came onto the scene when it announced its seed round in July 2022 from the likes of Miami Marlins co-owner Roger Ehrenberg (IA Sports Ventures and Eberg Capital), Betr & Simplebet founder Joey Levy, NBA All-Star Richard Jefferson, among others. Since then, they have launched a community-driven content network receiving over 10 Million impressions a month, announced partnerships with Sparket, Wagr and released multiple data findings from a survey of bettors and non-bettors that discovered that education was the biggest barrier for would-be sports bettors. For more information on WagerWire and to sign-up for early access visit WagerWire.com. Join the community on Twitter @WagerWire and on TikTok @WagerWireLive. WagerWire believes that all bettors should have the right to access the full value of their sports bets. WagerWire empowers you to take control of your action and view your bets as a portfolio of assets that can be bought and sold at any time. Seamlessly sync your favorite sportsbooks to track the real-time value of your bets, stack rewards, and play with celebrities or friends. WagerWire is dedicated to providing users with a responsible gaming environment. Not only is it our mission to provide the most entertaining gambling experience, but it is also our duty to help prevent compulsive usage of and underage access to our gaming products. We are committed to responsible gaming. If you have a gambling problem and want help, call 1-800-GAMBLER Contact Details Bailey Irelan birelan@hotpaperlantern.com Company Website https://www.wagerwire.com/

May 02, 2023 09:02 AM Eastern Daylight Time

Article thumbnail News Release

Former L'Oréal President Jim Morrison, Chief Executive Officer of Emergent Health Corp. Reports Year to Year Revenue Increase of Over 380% and Quarter to Quarter Revenue Increase of Over 100%

Emergent Health Corp.

Emergent Health Corp. (OTC: EMGE), a curator, developer, and marketer of products in the Regenerative Health Space announced today announced revenues of $373,406 for the quarter ended December 31, 2022 as compared to $185,471 for the quarter ended September 30, 2022, an increase of over 100% and revenues of $574,613 for the Year Ended December 31, 2022 as compared to $119,567 for the year ended December 31, 2021, an increase of over 380%. The financial statement can be viewed in its entirety at: https://www.otcmarkets.com/otcapi/company/financial-report/367945/content. Jim Morrison, former L'Oréal President and Emigrant’s new full time CEO stated, “The company is now engaged with several large biologics companies, and we expect enormous growth over the second and third quarter.” Emergent projects to continue increasing its revenues quarter to quarter as it expands its business internally and externally by acquisition. Recent Developments: On February 23, 2023, announced that it anticipates closing the acquisition to acquire Nanosthetic Cosmetic Labs (“Nanosthetic”) shortly. Nanosthetic, of Fort Lauderdale Florida, holds proprietary intellectual property that has been developed over the past ten years. The press release can be viewed in its entirety here. On February 21, 2023, Emergent on behalf of its subsidiary, Evolutionary Biologics, Inc., announced that it has executed a Letter of Intent to acquire a privately held company in the regenerative medical field. The company is profitable and does $5.4 Million in current revenues and projects a total of $9 Million in revenues for 2023. The press release can be viewed in its entirety here. The global biologics market size was valued at US $366.43 billion in 2021 and it is expected to hit over US$ 719.84 billion by 2030 with a noteworthy CAGR of 7.8% from 2022 to 2030. A biologic medication is a product that is made from live organisms and contains living organism components. Examples of biologics are Recombinant protein, tissues, allergens, genes, cells, blood components, blood, and vaccinations are all examples of biologics. Examples of what can be treated are Anemia, hemophilia, chronic migraine, hepatitis B, rheumatoid arthritis, inflammatory bowel disease, and other disorders and infections are treated with biologics. Our focus is on aesthetics cosmetics and men’s and women’s health, but also wound care and tissue regeneration. Various government efforts, higher share of biologics in the market, and rising use of biopharmaceuticals over chemically produced molecules, and many other factors are driving the biologics market expansion in the forecast period. ABOUT EMERGENT HEALTH CORPORATION Emergent curates, develops and sells products in the Regenerative Health Space. Its products comprise of ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. Its subsidiaries; PharmaZu, is a pure play, e-commerce products and service provider focused on the Pet Community, Pet Pharmacy and Pet Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses; Regen BioWellness, is a distributor of various products in the plant-based and regenerative medical fields. Evolutionary Biologics, is a new kind of biologics company founded for a clear purpose: bring cutting edge regenerative products to the medical community. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease. For more information, please visit Emergent's Website and Social Media on Twitter. Before using any products, you should always consult with your Veterinarian and/or Family Doctor. SAFE HARBOR STATEMENT This press release contains forward-looking statements that can be identified by terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. FOR MORE INFORMATION, PLEASE CONTACT: Jim Morrison, CEO Emergent Health Corporation Website i nfo@emergenthealthcompany.com Contact Details Emergent Health Corp. info@emergenthealthcompany.com Company Website https://emergenthealthcompany.com/

May 02, 2023 09:00 AM Eastern Daylight Time

Article thumbnail News Release

LITTLE SAINTS INTRODUCES ST. MEZCAL, THEIR FIRST NON-ALCOHOLIC SPIRIT, INTO THEIR PORTFOLIO OF PLANT MAGIC BEVERAGES

Little Saints

Little Saints, the only mocktail brand to combine Reishi mushrooms, CBD and terpenes in their ingredients –a formula expertly crafted by of a food scientist, environmentalist and a shaman– today expands their non-alcoholic offerings with the release of St. Mezcal. Known for its rich history and rituals of connection, Mezcal is the fastest growing spirit in the US and the least represented in the non-alcoholic space, making St. Mezcal the first functional alternative on the market. Little Saints is believed to be the first spirit producer (alcoholic or non-alcoholic) using a pure palo santo extract –sourced sustainably from Peru– as an ingredient in its St. Mezcal formula, which will be sold at a suggested retail price of $49.99 in a beautifully-designed, Mezcal-inspired 750ml glass bottle. Little Saints St. Mezcal ingredient profile is highly intentional with a complex blend of flavors and functional, sacred plants for a multi-sensory and mood-enhancing experience. The sophisticated, first-of-its-kind blend is highlighted by palo santo (a surprising blend of wood and fennel), ginger, cardamom and vanilla along with an added burn (from capsicum peppers) that hits your throat even when mixed into a blended beverage. It also delivers the rich smell profile associated with certain alcoholic spirits, like Mezcal. Inspired by, but not trying to replicate, the traditional alcoholic Mezcal spirit, St. Mezcal serves as an idyllic, delicious beverage option meant to be consumed neat or as a non-alcoholic replacement for mocktails and cocktail recipes. Little Saints St. Mezcal is joining the menus of today’s buzziest hottest bar and hotel menus including but not limited to Patent Pending (NYC), Clay (NYC), Saint Tuesday (NYC), La Noxe (NYC), Howard’s Bar and Club (Austin), Perla’s (Austin), Liz Lambert ’s Hotel Saint Vincent (New Orleans) and Austin Proper Hotel (Austin). Little Saints sources its palo santo extract, a fragrant wood known for its energy-cleansing and spiritual properties, directly from a forest in Northern Peru. Creating the pure palo santo extract was an extensive process the Little Saints team perfected alongside its Peruvian partners, over a year-long period to optimize the smell and taste of the extract, in addition to procuring a USDA timber permit to import directly from the Peruvian suppliers. The palo santo used to make the extract in St. Mezcal is harvested sustainably from dead and fallen trees, and a percentage of the proceeds of St. Mezcal goes back to the community in Peru that harvests it. Lion’s mane, an adaptogenic mushroom, has been added in 100mg/serving, a dosage adequate to boost brain power and creativity by stimulating the growth of neurons in the brain–the very thing alcohol negatively impacts. Out of all adaptogenic mushrooms, lion’s mane was included as a segue to better social dialogue and more meaningful interactions. The dosage is stated intentionally as it’s commonplace for brands to include the ingredient without dosage information to mask insufficient amounts for noticeable impact. According to NPR in 2023, the non-alcoholic beverage category is a $400m category in the United States, growing at 20% year or year. In comparison, the US alcoholic drinks market is a $284b market growing at a flat 7% per year. Consumers are seeking savvy, high quality choices. “ Most non-alcoholic spirits don’t hold up by themselves. Some of them are okay in cocktails, but I would never drink them on their own. St. Mezcal is one of two N/A spirits that I would ever drink neat or on the rocks, and I would prefer St. Mezcal out of those two. It is zero proof but it has a kick like a thunder. I want to highlight that it has a flavor balance and that it gets you in a nice mood. It does something to you… It’s not just like I’m not drinking and I’m good for the night. It will put you in a good mood. ” — Nikola Nikoletic, Head Bartender at Patent Pending NYC Little Saints was founded by environmental lawyer turned plant-based foods entrepreneur, Megan Klein, and shaped by a female food scientist with a Masters in adaptogens (plants that help the body adapt to stress). As a woman-led company, Little Saints sets out to elevate emotional wellbeing and to encourage connectivity with nature. Launched at music festivals from day one, the brand embodies play in all its forms. It is the mocktail and spirit to drink for a consequence-free mood lift. “St. Mezcal takes the non-alcoholic spirit game up a notch, adding a mood-enhancing ingredient to traditional mocktail menus. I wanted to pair something sensory and spiritual like palo santo with something highly efficacious like lion’s mane. I use both in my everyday life, and I see the benefits - the palo santo helps me clear negative energy and feel creative, and the lion’s mane activates my brain and gives me a buzz that helps me feel creative, focused and playful.” —  Megan Klein, Founder and CEO of Little Saints. Little Saints' bold flavored non-alcoholic drinks are designed to provide an uplifting sensory experience through thoughtfully combined plant magic ingredients. With the philosophy that play is wellness, their mission is to inspire indulgence in art, movement and connection with their community via the canned ready-to-drink plant magic mocktails and new St. Mezcal spirit. Through sourcing, partnerships and distribution purchasing decisions, Little Saints promotes environmental sustainability and conscious capitalism. With integrity and an open mind, Little Saints serves the community by donating more than 1% of its revenue to organizations fostering equity in relation to plant medicine and mental health. Little Saints St. Mezcal is the brand’s first entry point into the spirit world, but certainly not the last as the brand looks to expand functional, delicious offerings in the non-alcohol mocktail and spirit space. About Little Saints Little Saints is a brand of plant magic beverages inspired by our deep reverence for plants and equally deep commitment to play. Working with functional ingredients sourced from sacred plants—plants with special spiritual and curative properties—Little Saints creates non alcoholic, sugar-free plant magic mocktails and spirits. With flavors inspired by classic cocktails —like Paloma, Spicy Margarita, Ginger Mule, Negroni Spritz, and Mimosa—the ready-to-drink mocktails are sugar free and formulated with Little Saints proprietary blend of Reishi mushroom, CBD and botanical terpenes, and the new St. Mezcal spirit continues their mission of providing consumable functional benefits without the alcohol but with the joy. This plant magic "stack" was created in collaboration with Little Saints' adaptogen-expert food scientist and sacred-plant-medicine shaman to inspire positive emotions and a lifted spirit. The brand debuted in 2021, launching first at outdoor festivals throughout Michigan where Megan served mocktails from the back of a mint-green trailer to attendees intrigued by the unique option of an uplifting, natural, clean, and alcohol-free alternative. Since then, the brand has gone national and is already an industry favorite, staking its claim within the non-alcoholic beverage space which continues to grow exponentially faster than the alcoholic space–a signal of a growing cultural shift. Little Saints is at the forefront of a growing movement of an intentional wellness focused lifestyle that eschews drinking alcohol in favor of healthier options. Little Saints is available at select specialty retailers nationwide, including Erewhon in Los Angeles, Berkeley Bowl in San Francisco, as well as non-alcoholic bottle shops such as Spirited Away, Minus Moonshine, and Sechey in New York. The suggested retail price is $5.99 per 8oz can and $49.99 for St. Mezcal per 750ml bottle. For additional information on Little Saints, check out the website littlesaints.com and follow the brand on Instagram at @littlesaintsco. About Founder Megan Klein Megan Klein, Little Saints' Founder + CEO, is a longtime advocate for plant-inspired living. As an environmental lawyer early in her career for Earthjustice, Megan fought against frackers and factory farm polluters. Later, she became a modern farmer, running the country's largest vertical farm and playing a role in the burgeoning local food movement in the Midwest. As an extension of her work in local foods, in 2017 Megan founded Field + Farmer a plant-based food and beverage brand sold in grocery stores throughout the U.S. While running that company, Megan enrolled in the Kellogg School of Management, where she was when the pandemic hit—and when her thoughts turned to emotional healing. Megan founded Little Saints in May 2021 in Detroit and has since moved herself and the company to Miami. Contact Details Little Saints Amanda Smeal amanda@amandasmeal.com Company Website https://littlesaints.com

May 02, 2023 08:03 AM Eastern Daylight Time

Image
Article thumbnail News Release

FTN Network Leverages Strong Q1 2023 Growth to Close $500k Bridge Round From Techstars Sports Accelerator

FTN

FTN Network, a data company specializing in delivering affordable, customizable, extraordinarily detailed and accurate data for betting, season-long fantasy and daily fantasy today announced the closing of its $500,000 Bridge Round, which oversubscribed; with the help of Techstars, a global accelerator for technology startups. FTN was selected to participate in the Techstars Sports Accelerator Powered by Indy program in Indianapolis in April 2022. FTN is now actively raising a $3–5 million seed round to help expedite and scale the company, building on its robust early growth in traffic, subscription revenues and social media engagement. More specifically: Q1 2023 traffic was up 54% (year-over-year) across the FTN network of sites. Q1 2023 subscription revenue was up 34% (year-over-year) across the FTN network of sites. FTN YouTube views are up 32% (year-over-year) and overall subscribers are up 31% (year-over-year). FTN Podcast Network downloads are up 25% (year-over-year) “Our goal and mission with FTN was to create a fantasy and sports betting data company that allowed any user — from those with a limited budget to a top-of-the-line sportsbook — the flexibility to use our data and tools in ways that fit their specific needs. We never wanted to box our customers into a rigid system. Our exemplary year-over-year results are proof that our vision is filling a great need in the market,” said Kevin Adams, CEO of FTN Network. “The closing of our bridge round from the Techstars Accelerator is going to help us invest in areas of our business where we’re seeing strong engagement, create new strategic partnerships with providers, tech companies and sportsbooks, and expand our talent pool with new developers and advisors to continue scaling and building one of the most innovative sites in the industry.” In recent months, FTN has signed strategic partnerships with companies such as Sorare, Bettle and Prediction Strike, and rolled out two significant new tools which are gaining popularity with users and achieving significant traction in Google search results. First, its Same Game Parlay Tool on FTNBets.com takes APIs from the six largest US sportsbooks and compares a user's same game parlay line with FTN Data projections to create “True Odds.” This allows the user to stay away from bad payouts and shop for the best odds. Second is their Player Prop Tool, which shows the best player prop bets available using their FTN Data projections to calculate win%, edge and expected value while offering the best line on the market to place that bet. This allows users to leverage FTN Data to make the most educated player prop bets as possible. “As we look toward our next round of funding, our sights are focused on scaling our existing products and services, and integrating the NBA and PGA into FTN Data, all while expanding into the business-to-business (B2B) market with FTN Data. By investing in more charters (people watching games and collecting data in real time) we’ll have the ability to push our data to clients quicker, creating an opportunity for our users to make smarter and faster decisions,” said Stefano Vaccarino, FTN’s Chief Marketing Officer. “We at FTN are relentless in our approach to innovation and our goal of providing the most customizable data sets and products for each customer or corporation.” For more information on FTN’s products and services, please visit its network of sites: FTNFantasy.com, FTNDaily.com and FTNBets.com. About FTN Network FTN Network is a data and entertainment network for fantasy sports and betting. Founded in 2020, FTN Network’s family of sites include Fantasy, Daily Fantasy (DFS), Betting and Data. The company has over 50 content contributors to serve the fantasy sports and betting needs of fans across key sports, including NFL, NBA, MLB, NHL, PGA, eSports, Racing and more. About Techstars The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas — entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations and cities to help build thriving startup communities. Techstars has invested in more than 2,500 companies with a combined market cap of more than $220B. Contact Details Hot Paper Lantern Sterling A. Randle +1 801-319-6153 srandle@hotpaperlantern.com

May 01, 2023 12:35 PM Eastern Daylight Time

1 ... 7778798081 ... 309